Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
08/27/18 GEM036 Hematopoietic stem cell fucosylation Prevention of infection & GvHD from hematopoietic stem cell transplantation see Note Phase 3 ready with FDA SPA In Phase II study:
Statistically significant acceleration of immune system reconstitution
(neutrophil/platelet recovery)
Significantly reduced infection and GvHD
Improved survival
Positioned to be best-in-classNo
reports of adverse event specifically attributable to fucosylation

08/07/18 GEM035 An anti-ENO1 antibody Immune diseases, various cancers SC Preclinical (close to IND) Showed efficacy in animal models of multiple sclerosis, RA, pancreatic cancer and liver cancer.
Also applicable to IBD and COPD etc.
Completed pre-clinical studies including monkey toxicity studies, GMP production.
08/07/18 GEM034 Derivative of neuroprotective protein Stroke, Huntington chorea, Schizophrenia and PTSD IV Preclinical A cell-permeable recombinant peptide.
Can cross the blood-brain barrier, is resistant to degradation, and can bind constitutively to its substrates.
Significantly reduces brain damage in rodent stroke model.
Expected to be treated after stroke without diagnosis of stroke type before dosing.
08/07/18 GEM033 Inhibitors of bacterial resistance mechanisms Gram-negative MDR bacterial infections, lung infections in cystic fibrosis (CF) patients see Note Preclinical Restore effectiveness of shelved antibiotics.
Lower the effective dose of antibiotics.
Mitigate antibiotic resistance.
Disrupt biofilm-based infections.
Over 1,000 compounds with lead compounds for each indication identified.

Route : Intravenous, Aerosol, Topical
07/26/18 GEM032 Calcium release-activated calcium channel inhibitor Respiratory & immuno-inflammatory diseases Oral Phase 1 - Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation.
- Phase 1 SAD/MAD study were completed.
07/26/18 GEM031 Calcium release-activated calcium channel inhibitor Lymphomas & Solid cancer Oral Phase 1 - Demonstrated preclinical activity in a broad range of cancers.
- Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing.
07/26/18 GEM030 PI3K δ/γ dual inhibitor Hematological malignancies, T cell Lymphoma, Hodgkin Lymphoma Oral Phase 2 - Highly specific dual PI3K δ/γ inhibitor with nano‐molar inhibitory potency
- Single-agent and combination with immune checkpoint inhibitor programs
- Inhibits primary patient leukemic/lymphoma cells
- Dose escalation study demonstrated an acceptable safety and tolerability with promising clinical activity
07/20/18 GEM029 A cancer stem cell-associated transcription factor inhibitor Malignant gliomas including glioblastoma (GBM) Oral Phase 1 ready -Directly kills the cancer stem cells.
-Significantly improves survival in orthotopic GBM PDX models.
-Inhibits tumor growth in a mouse implanted with GBM cells and the growth inhibition is augmented by combination with temozolomide/radiation.
-No significant toxicities are identified at therapeutic doses.
07/09/18 GEM028 miRNA targeting refractory colon cancer with mutated K-ras and refractory pancreatic cancer pancreatic cancer colon cancer IV Preclinical The miRNA regulates K-ras, Bcl2, survivin, and NF-kB and demonstrate excellent antitumor effect in vitro and in vivo. Contact
07/09/18 GEM027 miRNA targeting refractory colon cancer with mutated K-ras colon cancer IV Preclinical The miRNA regulates EGFR signaling pathway by directly inhibiting of both KRAS and AKT1 and demonstrate excellent antitumor effect in vitro and in vivo. Contact